The global growth of Computed Tomography (CT) procedures is leading to increased global demand for iodine contrast media (ICM). Based on this advancement, we estimate that demand for contrast media will continue to increase in the coming years1.
In order to address this growing demand, significant continued capacity investment is required to ensure secure future supply and peace of mind for clinicians across radiology suites and interventional departments globally.
This includes our 4 STEP PLAN: from extraction to injection
1. Securing and Protecting Iodine Supply1
GE HealthCare have established a multi-year agreement with SQM, a Chile-based mining company as well as long-term supply agreements in Japan. This will enable us to secure increasing supply of iodine, a key ingredient for contrast media products used in X-Ray and CT imaging procedures.
The agreement will see an increased supply of iodine raw material year-on-year to enable the production of 30% more patient doses of ICM annually by 20251.
2. Producing More API For More Iodine Contrast Media
In our Lindesnes site, we are investing $80 million to expand our active pharmaceutical ingredient (API) capacity by ~30% by 20251.
3. Producing More Doses in Our Secondary Manufacturing Fill and Finish Sites
We’re investing to expand capacity at our Secondary Manufacturing Fill and Finish Sites to produce ~30% more patient doses by 20251.
As part of this, GE HealthCare are investing in production capacity to help meet this growing demand, including the opening of a new $30 million production line at our Secondary Manufacturing Fill and Finish Site in Cork, Ireland, to grow capacity there by 30%.
4. Maximized Usage of ICM by enabling personalized dosing, reducing wasted contrast media, and improving workflow
To enable more patient throughput, and personalized dosing we are:
- Manufacturing new scanners with smart protocols, AI and other tools to help deliver the right patient dose.
- Producing more iodine contrast media in larger, +PLUSPAK™ polymer packaging, improving workflow and reducing downtime from breakages and metal ring pull injuries.
Costs are Increasing
Price of iodine has increased by more than 200% from 2017 to 20231
Production costs for iodine contrast media have increased year on year
Learn more about how we are securing our iodine supply
If you want to learn more about how we are securing our iodine supply, please complete the form below and we will get in touch as soon as possible.
Prescribing Information
Please see OmnipaqueTM prescribing information here for:
Sweden | Denmark | Finland | Norway | Netherlands | BELUX(NL) | BELUX(FR)
Please see VisipaqueTM prescribing information here for:
Sweden | Denmark | Finland | Norway | Netherlands | BELUX(NL) | BELUX(FR)
Reporting Adverse Events
GE HealthCare has a legal and ethical responsibility to protect the public health and therefore we ensure safety and efficiency for our products.
In order to do so, we collect reports about suspected adverse events that the patients experience during or after they are exposed to our products.
We also collect information about special situations (such as exposure during pregnancy, overdose, etc. ) as well as customer complaints and other views from customers about our products.
To report a suspected adverse event/special situation, customer complaint or just to share your views about our products, please contact:
For Sweden: [email protected] | Phone: +46 (0)200 895473
For Finland: [email protected] | Phone: +358 (0)800 919 427
For Denmark: [email protected] | Phone: +45 88 95 14 or +45 70 22 22 03
For Norway: [email protected] | Phone: +47 (0)23 18 79 58
For Netherlands: [email protected] | Phone: +31 (0)40 299 1111
For BELUX: [email protected] | Phone: French +32 (0)80 04 96 18 | Dutch +32 (0)80 03 89 97
REFERENCES
- Data on file – Contrast Media Demand and Investment; November 2023
GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe
GE Healthcare Limited, Pollards Wood, Nightingales Lane, Chalfont St Giles, Buckinghamshire, England HP8 4SP
© 2024 GE HealthCare
Omnipaque and Visipaque are trademarks of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.
05- 2024 | JB00114NEU
Welcome to GE Healthcare
The content on this website is intended only for an audience of Healthcare Professionals located in Northern Europe. If you are from a country other than Northern Europe, please visit the GEHealthcare.com Global Gateway and select your country.
Are you a healthcare professional from Northern Europe (SE,DK,FI,NO,NLD, BELUX)?
Yes No